Autoimmune/Inflammatory Arthritis Associated Lymphomas: Who Is at Risk?

Overview

Journal Biomed Res Int

Publisher Wiley

Specialties Biomedical Engineering
Biotechnology
General Medicine

Date 2016 Jul 19

PMID 27429984

Citations 22

Authors

Sujani Yadlapati

Petros Efthimiou

Affiliations

Soon will be listed here.

Abstract

Specific autoimmune and inflammatory rheumatic diseases have been associated with an increased risk of malignant lymphomas. Conditions such as rheumatoid arthritis (RA), primary Sjögren's syndrome (pSS), systemic lupus erythematosus (SLE), dermatomyositis, and celiac disease have been consistently linked to malignant lymphomas. Isolated cases of lymphomas associated with spondyloarthropathies and autoinflammatory diseases have also been reported. Direct association between autoimmunity and lymphomagenesis has been reinforced by large epidemiological studies. It is still uncertain whether disease specific determinants or phenotypic or treatment related characteristics increase likelihood of lymphomagenesis in these patients. For example, recent literature has indicated a positive correlation between severity of inflammation and risk of lymphomas among RA and Sjögren's syndrome patients. It is also debated whether specific lymphoma variants are more commonly seen in accordance with certain chronic autoimmune arthritis. Previous studies have revealed a higher incidence of diffuse large B-cell lymphomas in RA and SLE patients, whereas pSS has been linked with increased risk of mucosa-associated lymphoid tissue lymphoma. This review summarizes recent literature evaluating risk of lymphomas in arthritis patients and disease specific risk determinants. We also elaborate on the association of autoimmune arthritis with specific lymphoma variants along with genetic, environmental, and therapeutic risk factors.

Citing Articles

Integrating electronic health records and GWAS summary statistics to predict the progression of autoimmune diseases from preclinical stages.

Wang C, Markus H, Diwadkar A, Khunsriraksakul C, Carrel L, Li B Nat Commun. 2025; 16(1):180.

PMID: 39747168 PMC: 11695684. DOI: 10.1038/s41467-024-55636-6.

Survival after surgery for lung cancer among patients with autoimmune diseases.

Nagano M, Cong Y, Nakao K, Kawashima M, Konoeda C, Sato M Surg Today. 2024; .

PMID: 39320491 DOI: 10.1007/s00595-024-02917-8.

Histological differences related to autophagy in the minor salivary gland between primary and secondary types of Sjögren's syndrome.

Ono-Minagi H, Nohno T, Takabatake K, Tanaka T, Katsuyama T, Miyawaki K BMC Oral Health. 2024; 24(1):1099.

PMID: 39285388 PMC: 11406829. DOI: 10.1186/s12903-024-04869-4.

Dermatomyositis Associated With High-Grade B-Lymphoproliferative Disorders: A Case Report and Literature Review.

Ng J, Mokoonlall M, Kawatu H, Ayyalil F, Perera C, Morey A J Investig Med High Impact Case Rep. 2024; 12:23247096241262702.

PMID: 39077815 PMC: 11289793. DOI: 10.1177/23247096241262702.

Global spatiotemporal distributions of lymphoma from 1990 to 2019: A Joinpoint regression analysis based on the global burden of disease study 2019, and projections until 2044.

Liu J Dialogues Health. 2024; 4:100182.

PMID: 38846580 PMC: 11153881. DOI: 10.1016/j.dialog.2024.100182.

References

Buchbinder R, Barber M, Heuzenroeder L, Wluka A, Giles G, Hall S . Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum. 2008; 59(6):794-9. DOI: 10.1002/art.23716. View

Gross R, Schwartzman-Morris J, Krathen M, Reed G, Chang H, Saunders K . A comparison of the malignancy incidence among patients with psoriatic arthritis and patients with rheumatoid arthritis in a large US cohort. Arthritis Rheumatol. 2014; 66(6):1472-81. PMC: 4059038. DOI: 10.1002/art.38385. View

Baecklund E, Iliadou A, Askling J, Ekbom A, Backlin C, Granath F . Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum. 2006; 54(3):692-701. DOI: 10.1002/art.21675. View

Yoshida Y, Takahashi Y, Yamashita H, Kano T, Kaneko H, Mimori A . Clinical characteristics and incidence of methotrexate-related lymphoproliferative disorders of patients with rheumatoid arthritis. Mod Rheumatol. 2014; 24(5):763-5. DOI: 10.3109/14397595.2013.878016. View

Ambrosetti A, Zanotti R, Pattaro C, Lenzi L, Chilosi M, Caramaschi P . Most cases of primary salivary mucosa-associated lymphoid tissue lymphoma are associated either with Sjoegren syndrome or hepatitis C virus infection. Br J Haematol. 2004; 126(1):43-9. DOI: 10.1111/j.1365-2141.2004.04993.x. View

Liang Y, Yang Z, Qin B, Zhong R . Primary Sjogren's syndrome and malignancy risk: a systematic review and meta-analysis. Ann Rheum Dis. 2013; 73(6):1151-6. DOI: 10.1136/annrheumdis-2013-203305. View

Kandiel A, Fraser A, Korelitz B, Brensinger C, Lewis J . Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut. 2005; 54(8):1121-5. PMC: 1774897. DOI: 10.1136/gut.2004.049460. View

Mercer L, Davies R, Galloway J, Low A, Lunt M, Dixon W . Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population. Rheumatology (Oxford). 2012; 52(1):91-8. PMC: 3521445. DOI: 10.1093/rheumatology/kes350. View

Sigurgeirsson B, Lindelof B, Edhag O, Allander E . Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study. N Engl J Med. 1992; 326(6):363-7. DOI: 10.1056/NEJM199202063260602. View

10.

Parikh-Patel A, White R, Allen M, Cress R . Risk of cancer among rheumatoid arthritis patients in California. Cancer Causes Control. 2009; 20(6):1001-10. PMC: 4354853. DOI: 10.1007/s10552-009-9298-y. View

11.

Ehrenfeld M, Abu-Shakra M, Buskila D, Shoenfeld Y . The dual association between lymphoma and autoimmunity. Blood Cells Mol Dis. 2002; 27(4):750-6. DOI: 10.1006/bcmd.2001.0442. View

12.

Baimpa E, Dahabreh I, Voulgarelis M, Moutsopoulos H . Hematologic manifestations and predictors of lymphoma development in primary Sjögren syndrome: clinical and pathophysiologic aspects. Medicine (Baltimore). 2009; 88(5):284-293. DOI: 10.1097/MD.0b013e3181b76ab5. View

13.

Rohekar S, Tom B, Hassa A, Schentag C, Farewell V, Gladman D . Prevalence of malignancy in psoriatic arthritis. Arthritis Rheum. 2008; 58(1):82-7. DOI: 10.1002/art.23185. View

14.

Wolfe F, Michaud K . The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum. 2007; 56(5):1433-9. DOI: 10.1002/art.22579. View

15.

Ekblom-Kullberg S, Kautiainen H, Alha P, Leirisalo-Repo M, Julkunen H . Smoking and the risk of systemic lupus erythematosus. Clin Rheumatol. 2013; 32(8):1219-22. DOI: 10.1007/s10067-013-2224-4. View

16.

Cohen S, Petryk M, Varma M, Kozuch P, Ames E, Grossbard M . Non-Hodgkin's lymphoma of mucosa-associated lymphoid tissue. Oncologist. 2006; 11(10):1100-17. DOI: 10.1634/theoncologist.11-10-1100. View

17.

Thomas E, Brewster D, Black R, Macfarlane G . Risk of malignancy among patients with rheumatic conditions. Int J Cancer. 2000; 88(3):497-502. View

18.

Askling J, Fored C, Baecklund E, Brandt L, Backlin C, Ekbom A . Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis. 2005; 64(10):1414-20. PMC: 1755232. DOI: 10.1136/ard.2004.033241. View

19.

Baecklund E, Backlin C, Iliadou A, Granath F, Ekbom A, Amini R . Characteristics of diffuse large B cell lymphomas in rheumatoid arthritis. Arthritis Rheum. 2006; 54(12):3774-81. DOI: 10.1002/art.22277. View

20.

Bernatsky S, Ramsey-Goldman R, Labrecque J, Joseph L, Boivin J, Petri M . Cancer risk in systemic lupus: an updated international multi-centre cohort study. J Autoimmun. 2013; 42:130-5. PMC: 3646904. DOI: 10.1016/j.jaut.2012.12.009. View